Impact of AI on Health Care and Pharma

As a Futurist advisor to over 400 of the world's largest companies including many health care / pharma giants, as well as leading AI companies such as Google and Microsoft, Patrick Dixon is one of the world's leading authorities on the impact of AI on future health care.  Dr Dixon is also a physician, who originally specialised in oncology / care of the dying.

Here is an example of a keynote outline - each is fully customised in close consultation with clients.

AI (Artificial Intelligence) will drive astonishing improvements in health care, saving tens of millions of lives over the next few decades alone.

Over EU30bn is already being spent globally on AI innovations in health care each year, growing 30% pa. 

95% of health care companies are now using AI, spending 10% of their collective turnover on AI. 

AI has the potential to reduce health costs by up to 10% per episode of care over the next two decades, saving $300bn in the US alone.Just one area in which AI will save health costs will be streamlining $4tn in medical invoicing across the US.

EU200bn will also be saved by AI each year in EU nations by 2040, 10% of this AI-linked impact will be linked to wearable tech (1bn people globally own such devices).

Overall staffing and health budgets will continue to grow because of ageing populations, new treatment options and rising expectations, despite cost savings using Artificial Intelligence.

AI will rapidly improve diagnostics (resulting in much earlier treatment).

AI will ensure better use of hospital beds (faster discharge).

AI will enable huge growth of Virtual Wards, linked to AI-driven MedTech at home.

In all this AI-related health care innovation, day to day experience in hospital for someone unwell will feel relatively unchanged.

AI will remain primarily in background, supporting health workers in better decision-making, and accelerating innovation, with implications for future training.

AI will also create new risks in health care from inappropriate use, AI errors, and more severe cyberattacks.

Impact of AI on Pharma - innovation, drug discovery, clinical trials, drug approvals

AI will also transform Pharma, already doing so. AI will speed up "genetic prophecy".

AI will radically shake up every aspect of drug discovery and early lab testing.

AI will accelerate patient recruitment into clinical trials (shortening drug trial length in some cases).

AI will save time scanning medical research literature, speed clinical trial report writing and research data analysis.

AI will accelerate submissions for regulatory approval of new drugs.

Read on - buy my new book NOW AI Will Change Your Life".

* Dr Patrick Dixon is Chairman of Global Change Ltd, and advisor to many of the world’s largest pharmaceutical companies, health care and medtech companies. Author of 19 books including "The Future of Almost Everything”, his latest book is "Life with AI - how to survive and succeed in a super-smart world”, (September 2024 launch). It contains two chapters covering AI impact on health care and pharma. He originally trained as an oncology physician and has worked in the past with GSK, helping to identify new potential blockbusters, and as a keynote speaker. He has previously Chaired a BioTech startup, pioneering oncolytic viruses to destroy solid tumours in Phase I and Phase IIa clinical trials, later bought by a larger BioTech company.

Every keynote is unique, customised in close consultation with event organisers to create a highly interactive, engaging, entertaining and sharply relevant audience experience. Medical clients in addition to GSK include Genentech, Roche, Novartis, Wyeth Pharmaceuticals, Gillette, Johnson and Johnson, Sanofi, Bayer, Merck, Novo Nordisk, 3M, Avon, L'Oreal, Siemens Medical, Phillips Diagnostics, Hoffmann LaRoche, TEVA Pharma, Reckitt Benckiser, Falck, BUPA, Astellas Pharma, Ottobock, Coloplast, Henry Schein, NHS, Smith and Nephew, Leica Microsystems.